The venture capital firm specialises in backing spinouts and has already celebrated an exit with the flotation of Amsterdam UMC’s Lava Therapeutics.
Pureos Bioventures, a Switzerland-based venture capital firm backed by undisclosed strategic investors in life sciences, has extended the size of its first fund to $205m.
The final closing of BB Pureos Bioventures will target a portfolio of 17 to 20 pre-clinical and clinical-stage companies in Europe developing biological drugs and emerging modalities such as nucleic acid, cell and gene therapies.
Many companies in the fund’s portfolio are spinouts, including Amsterdam University Medical Centers’s immuno-oncology therapy developer Lava Therapeutics…
